Browse ANKRD11

Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Localizes to chromatin during prometaphase.
Domain PF00023 Ankyrin repeat
PF12796 Ankyrin repeats (3 copies)
Function

Chromatin regulator which modulates histone acetylation and gene expression in neural precursor cells (By similarity). May recruit histone deacetylases (HDACs) to the p160 coactivators/nuclear receptor complex to inhibit ligand-dependent transactivation (PubMed:15184363). Has a role in proliferation and development of cortical neural precursors (PubMed:25556659). May also regulate bone homeostasis (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001701 in utero embryonic development
GO:0001894 tissue homeostasis
GO:0010171 body morphogenesis
GO:0035264 multicellular organism growth
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0048705 skeletal system morphogenesis
GO:0048871 multicellular organismal homeostasis
GO:0060249 anatomical structure homeostasis
GO:0060323 head morphogenesis
GO:0060324 face development
GO:0060325 face morphogenesis
GO:0060348 bone development
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ANKRD11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ANKRD11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.47; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ANKRD11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.110.697
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3410.851
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0650.964
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0560.824
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0680.982
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0430.992
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1750.661
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1460.933
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5350.783
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.630.673
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1550.59
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0460.418
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ANKRD11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ANKRD11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ANKRD11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ANKRD11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ANKRD11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ANKRD11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ANKRD11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolANKRD11
Nameankyrin repeat domain 11
Aliases LZ16; T13; ANCO-1; ankyrin repeat-containing cofactor 1; nasopharyngeal carcinoma susceptibility protein; An ......
Chromosomal Location16q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ANKRD11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.